Evan J Zasowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3638331/publications.pdf

Version: 2024-02-01

32	1,309	16	30
papers	citations	h-index	g-index
33	33	33	1743
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	178
2	The Î²â€Łactams Strike Back: Ceftazidimeâ€Avibactam. Pharmacotherapy, 2015, 35, 755-770.	2.6	160
3	Vancomycin Exposure in Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: How Much Is Enough?. Clinical Infectious Diseases, 2014, 59, 666-675.	5.8	139
4	Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infections. Clinical Infectious Diseases, 2016, 62, 1242-1250.	5.8	99
5	Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	96
6	Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Open Forum Infectious Diseases, 2019, 6, ofz522.	0.9	85
7	Daptomycin Plus \hat{I}^2 -Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study. Clinical Infectious Diseases, 2020, 71, 1-10.	5.8	79
8	Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	60
9	Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Antimicrobial Agents and Chemotherapy, 2016, 60, 5841-5848.	3.2	58
10	Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. International Journal of Antimicrobial Agents, 2020, 56, 106184.	2.5	48
11	Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	43
12	Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. Clinical Infectious Diseases, 2019, 68, 1650-1657.	5.8	42
13	Characterization of the haematological profile of 21 days of tedizolid in healthy subjects. Journal of Antimicrobial Chemotherapy, 2016, 71, 2553-2558.	3.0	39
14	Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: Prevalence and risk factors. Diagnostic Microbiology and Infectious Disease, 2017, 89, 61-66.	1.8	28
15	Relationship between Time to Clinical Response and Outcomes among Pneumonia Outcomes Research Team (PORT) Risk Class III and IV Hospitalized Patients with Community-Acquired Pneumonia Who Received Ceftriaxone and Azithromycin. Antimicrobial Agents and Chemotherapy, 2014, 58, 3804-3813.	3.2	21
16	Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 877-881.	3.0	17
17	Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis. Infectious Diseases and Therapy, 2018, 7, 135-146.	4.0	14
18	Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime–Avibactam. Infectious Diseases and Therapy, 2020, 9, 291-304.	4.0	12

#	Article	IF	Citations
19	Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant <i>Staphylococcus aureus </i> Bloodstream Infection. Open Forum Infectious Diseases, 2022, 9, ofab606.	0.9	12
20	Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It's Complicated. Infectious Diseases and Therapy, 2019, 8, 627-640.	4.0	11
21	Novel application of published risk factors for methicillin-resistant S. aureus in acute bacterial skin and skin structure infections. International Journal of Antimicrobial Agents, 2018, 51, 43-46.	2.5	10
22	The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin. Open Forum Infectious Diseases, 2019, 6, ofz079.	0.9	10
23	Comparison of clinical outcomes and risk factors in polymicrobial versus monomicrobial enterococcal bloodstream infections. American Journal of Infection Control, 2016, 44, 917-921.	2.3	9
24	Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. International Journal of Antimicrobial Agents, 2019, 54, 346-350.	2.5	9
25	Withdrawn as Duplicate: The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin. Open Forum Infectious Diseases, 2019, 6, ofz077.	0.9	8
26	Role of Vancomycin Minimum Inhibitory Concentrations by Modified Population Analysis Profile Method and Clinical Outcomes in High Inoculum Methicillin-Resistant Staphylococcus aureus Infections. Infectious Diseases and Therapy, 2018, 7, 161-169.	4.0	7
27	Standardized Treatment and Assessment Pathway Improves Mortality in Adults With Methicillin-resistant <i>Staphylococcus aureus</i> Bacteremia: STAPH Study. Open Forum Infectious Diseases, 2021, 8, ofab261.	0.9	7
28	Comparison of outcomes between patients with single versus multiple positive blood cultures for Enterococcus: Infection versus illusion?. American Journal of Infection Control, 2016, 44, 47-49.	2.3	5
29	Risk Factors for Bloodstream Infections Among an Urban Population with Skin and Soft Tissue Infections: A Retrospective Unmatched Case-Control Study. Infectious Diseases and Therapy, 2019, 8, 75-85.	4.0	2
30	Reply to Cheng and Chuang. Clinical Infectious Diseases, 2019, 69, 903-904.	5.8	1
31	2379. Multicenter Evaluation of Ceftazidime–Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Open Forum Infectious Diseases, 2018, 5, S708-S709.	0.9	O
32	2384. Multidrug-Resistant Gram-Negative Infections Treated With Ceftolozane–Tazobactam: Impact of Delayed Initiation. Open Forum Infectious Diseases, 2018, 5, S710-S711.	0.9	O